Skip to main content
    K

    Keros Therapeutics Inc (KROS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.03
    -0.27 (-2.62%)

    Market Cap: $202.13M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Keros Therapeutics Inc (KROS) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Keros Therapeutics (KROS) trades at 4.9x sales and 0.7x book value. Its P/B of 0.7x is below its 5-year median of 3.6x. Its forward P/E is 48.8x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E48.8x
    Price to sales4.9x
    Price to book0.7x
    EV/FCF1.2x
    PEGN/A
    FCF yield-24.2%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B0.7x3.6xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 3 of the 6 year ends shown that have a P/S, its P/S ranged from 3.4x in 2025 to 177.7x in 2024.

    Year endPriceP/EP/SP/B
    2025$20.3611.2x3.4x2.5x
    2024$15.83N/A177.7x1.1x
    2023$39.76N/AN/A3.6x
    2022$48.02N/AN/A4.7x
    2021$58.51N/A68.2x5.6x
    2020$70.54N/AN/A5.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About KROS

    What is KROS's forward P/E ratio?

    Keros Therapeutics has a forward P/E ratio of 48.8x.

    Is KROS stock overvalued?

    GNG's valuation label for KROS is Undervalued.

    What is KROS's price to sales ratio?

    Keros Therapeutics has a price to sales ratio of 4.9x.